On Dec 7, 2018, Hansoh’s Ruiyisheng (Prucalopride Succinate Tablets) (available in 1mg and 2mg) received NDA approval from National Medical Products Administration to launch as a Category 4 first-to-market generic drug under the new classification system for registration of chemical drugs, equivalent to passing the consistency evaluation.

Prucipabride succinate is a highly selective 5-HT4 receptor agonist for the treatment of severe chronic constipation, which can significantly improve patients’ function of intestinal, reduce the severity of symptoms, and only need to be taken once a day.